|
gptkbp:instanceOf
|
Cannabinoid
|
|
gptkbp:actsOn
|
gptkb:CB1_receptor
gptkb:CB2_receptor
|
|
gptkbp:alsoKnownAs
|
gptkb:Delta-8-tetrahydrocannabinol
|
|
gptkbp:aroma
|
odorless
|
|
gptkbp:boilingPoint
|
175–178°C
|
|
gptkbp:canBeSynthesizedFrom
|
gptkb:Delta-9-THC
gptkb:CBD
|
|
gptkbp:CASNumber
|
5957-75-5
|
|
gptkbp:chemicalFormula
|
C21H30O2
|
|
gptkbp:color
|
colorless to pale amber
|
|
gptkbp:effect
|
relaxation
euphoria
anxiolytic effect
analgesic effect
antiemetic effect
appetite stimulation
|
|
gptkbp:excretion
|
kidneys
|
|
gptkbp:firstIsolatedFrom
|
1941
|
|
gptkbp:foundIn
|
Cannabis
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
D8
|
|
gptkbp:isomerOf
|
gptkb:Delta-9-tetrahydrocannabinol
|
|
gptkbp:legalStatus
|
varies by jurisdiction
|
|
gptkbp:marketedAs
|
hemp-derived product
|
|
gptkbp:meltingPoint
|
63–66°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
314.464 g/mol
|
|
gptkbp:notableFor
|
increasingly popular in US markets since 2018
less potent than Delta-9-THC
|
|
gptkbp:potentialForAbuse
|
moderate
|
|
gptkbp:psychoactive
|
true
|
|
gptkbp:relatedTo
|
gptkb:Delta-10-THC
gptkb:THC
gptkb:CBD
|
|
gptkbp:routeOfAdministration
|
oral
topical
inhalation
sublingual
|
|
gptkbp:sideEffect
|
anxiety
paranoia
red eyes
drowsiness
dry mouth
impaired coordination
|
|
gptkbp:solubility
|
lipid-soluble
|
|
gptkbp:subject
|
DEA regulation (in the US)
FDA regulation (in the US)
|
|
gptkbp:toxicity
|
low
|
|
gptkbp:usedFor
|
recreational purposes
medical purposes
|
|
gptkbp:bfsParent
|
gptkb:dice
|
|
gptkbp:bfsLayer
|
5
|